Integra Lifesciences Holdings (STU:IL3) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:IL3 Integra Lifesciences Holdings Corp STU:IL3
74 GF Score
Price €16.40
GF Value €20.79
Valuation Modestly Undervalued
! 11 Warning Signs
View Full Analysis

What is Integra Lifesciences Holdings Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Integra Lifesciences Holdings Valuation Rank Related Terms

STU:IL3
74GF Score
Integra Lifesciences Holdings Corp STU:IL3
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Integra Lifesciences Holdings (STU:IL3) Overvalued in 2026?

Based on GuruFocus' analysis, Integra Lifesciences Holdings stock appears to be undervalued. The current stock price of €16.40 is trading 21.1% below its estimated GF Value™ of €20.79. GuruFocus considers Integra Lifesciences Holdings to be Modestly Undervalued.

Key valuation signals for STU:IL3:

  • Valuation Rank:
  • GF Value™: €20.79 vs. price of €16.40 (21.1% below fair value)
  • GF Score™: 74/100 with 11 warning signs

No single metric tells the full story. See the STU:IL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Integra Lifesciences Holdings Business Description

Other Exchanges IART:USA
Address 1100 Campus Road, Princeton, NJ, USA, 08540
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
74GF Score

Get the complete analysis for STU:IL3

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.40
Price
€20.79
GF Value